Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups

Oncotarget

Volumn 5, Issue 9, 2014, Pages 2839-2852

  Simbolo, Michele ^a   Fassan, Matteo ^a   Ruzzenente, Andrea ^b   Mafficini, Andrea ^a   Wood, Laura D ^c   Corbo, Vincenzo ^a   Melisi, Davide ^a   Malleo, Giuseppe ^b   Vicentini, Caterina ^a   Malpeli, Giorgio ^a,b   Antonello, Davide ^a,b   Sperandio, Nicola ^a   Capelli, Paola ^a   Tomezzoli, Anna ^a   Iacono, Calogero ^b   Lawlor, Rita T ^a   Bassi, Claudio ^b   Hruban, Ralph H ^c   Guglielmi, Alfredo ^b   Tortora, Giampaolo ^a   de Braud, Filippo ^d   Scarpa, Aldo ^a   more..

^a UNIVERSITY AND HOSPITAL TRUST OF VERONA   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Cholangiocarcinoma; Molecular subclassification; Multigene mutational panels; Next generation sequencing; Target therapy

Indexed keywords

B RAF KINASE; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; TUMOR MARKER;

AGED; ARID1A GENE; ARTICLE; BAP1 GENE; BILE DUCT CARCINOMA; BILIARY TRACT CANCER; BRAF GENE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; GENE DOSAGE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; IDH1 GENE; IDH2 GENE; MAJOR CLINICAL STUDY; MALE; NRAS GENE; ONCOGENE; ONCOGENE K RAS; PBRM1 GENE; PIK3CA GENE; PREVALENCE; SIGNAL TRANSDUCTION; SMARCB1 GENE; BILE DUCT TUMOR; CANCER GRADING; CLASSIFICATION; ENZYME IMMUNOASSAY; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; GALLBLADDER TUMOR; GENETICS; HEPATIC DUCT; HIGH THROUGHPUT SEQUENCING; INTRAHEPATIC BILE DUCT; METABOLISM; MIDDLE AGED; MORTALITY; MUTATION; PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; SURVIVAL RATE;

AGED; BILE DUCT NEOPLASMS; BILE DUCTS, EXTRAHEPATIC; BILE DUCTS, INTRAHEPATIC; CHOLANGIOCARCINOMA; FEMALE; FOLLOW-UP STUDIES; GALLBLADDER NEOPLASMS; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; IMMUNOENZYME TECHNIQUES; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; MUTATION; NEOPLASM GRADING; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84901191451     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.1943     Document Type: Article

References (47)

1. Bosman FT, World Health Organization. and International Agency for Research on Cancer. (2010). WHO classification of tumours of the digestive system. (Lyon: International Agency for Research on Cancer).
2. Patel T. Cholangiocarcinoma--controversies and challenges. Nat Rev Gastroenterol Hepatol. 2011; 8:189-200.
3. Guglielmi A, Ruzzenente A, Campagnaro T, Pachera S, Valdegamberi A, Nicoli P, Cappellani A, Malfermoni G and Iacono C. Intrahepatic cholangiocarcinoma: prognostic factors after surgical resection. World J Surg. 2009; 33:1247-1254.
4. Ribero D, Pinna AD, Guglielmi A, Ponti A, Nuzzo G, Giulini SM, Aldrighetti L, Calise F, Gerunda GE, Tomatis M, Amisano M, Berloco P, Torzilli G and Capussotti L. Surgical Approach for Long-term Survival of Patients With Intrahepatic Cholangiocarcinoma: A Multi-institutional Analysis of 434 Patients. Arch Surg. 2012; 147:1107-1113.
5. Ribero D, Nuzzo G, Amisano M, Tomatis M, Guglielmi A, Giulini SM, Aldrighetti L, Calise F, Gerunda GE, Pinna AD and Capussotti L. Comparison of the prognostic accuracy of the sixth and seventh editions of the TNM classification for intrahepatic cholangiocarcinoma. HPB (Oxford). 2011; 13:198-205.
6. Guglielmi A, Ruzzenente A, Campagnaro T, Pachera S, Valdegamberi A, Capelli P, Pedica F, Nicoli P, Conci S and Iacono C. Does intrahepatic cholangiocarcinoma have better prognosis compared to perihilar cholangiocarcinoma? J Surg Oncol. 2010; 101:111-115.
7. Wang Y, Li J, Xia Y, Gong R, Wang K, Yan Z, Wan X, Liu G, Wu D, Shi L, Lau W, Wu M and Shen F. Prognostic nomogram for intrahepatic cholangiocarcinoma after partial hepatectomy. J Clin Oncol. 2013; 31:1188-1195.
8. Hezel AF, Deshpande V and Zhu AX. Genetics of biliary tract cancers and emerging targeted therapies. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2010; 28:3531-3540.
9. Ong CK, Subimerb C, Pairojkul C, Wongkham S, Cutcutache I, Yu W, McPherson JR, Allen GE, Ng CC, Wong BH, Myint SS, Rajasegaran V, Heng HL, Gan A, Zang ZJ, Wu Y, et al. Exome sequencing of liver fluke-associated cholangiocarcinoma. Nat Genet. 2012; 44:690-693.
10. Marsh Rde W, Alonzo M, Bajaj S, Baker M, Elton E, Farrell TA, Gore RM, Hall C, Nowak J, Roy H, Shaikh A and Talamonti MS. Comprehensive review of the diagnosis and treatment of biliary tract cancer 2012. Part I: diagnosis-clinical staging and pathology. J Surg Oncol. 2012; 106:332-338.
11. Sia D, Tovar V, Moeini A and Llovet JM. Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies. Oncogene. 2013; 32:4861-4870.
12. Fassan M, Baffa R and Kiss A. Advanced precancerous lesions within the GI tract: the molecular background. Best Pract Res Clin Gastroenterol. 2013; 27:159-169.
13. Jiao Y, Pawlik TM, Anders RA, Selaru FM, Streppel MM, Lucas DJ, Niknafs N, Guthrie VB, Maitra A, Argani P, Offerhaus GJ, Roa JC, Roberts LR, Gores GJ, Popescu I, Alexandrescu ST, et al. Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas. Nat Genet. 2013; 45:1470-1473.
14. Voss JS, Holtegaard LM, Kerr SE, Fritcher EG, Roberts LR, Gores GJ, Zhang J, Highsmith WE, Halling KC and Kipp BR. Molecular profiling of cholangiocarcinoma shows potential for targeted therapy treatment decisions. Human pathology. 2013; 44:1216-1222.
15. Borger DR, Tanabe KK, Fan KC, Lopez HU, Fantin VR, Straley KS, Schenkein DP, Hezel AF, Ancukiewicz M, Liebman HM, Kwak EL, Clark JW, Ryan DP, Deshpande V, Dias-Santagata D, Ellisen LW, et al. Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. Oncologist. 2012; 17:72-79.
16. Xu RF, Sun JP, Zhang SR, Zhu GS, Li LB, Liao YL, Xie JM and Liao WJ. KRAS and PIK3CA but not BRAF genes are frequently mutated in Chinese cholangiocarcinoma patients. Biomed Pharmacother. 2011; 65:22-26.
17. Chuang SC, Lee KT, Tsai KB, Sheen PC, Nagai E, Mizumoto K and Tanaka M. Immunohistochemical study of DPC4 and p53 proteins in gallbladder and bile duct cancers. World J Surg. 2004; 28:995-1000.
18. Tannapfel A, Sommerer F, Benicke M, Weinans L, Katalinic A, Geissler F, Uhlmann D, Hauss J and Wittekind C. Genetic and epigenetic alterations of the INK4a-ARF pathway in cholangiocarcinoma. J Pathol. 2002; 197:624-631.
19. Parwani AV, Geradts J, Caspers E, Offerhaus GJ, Yeo CJ, Cameron JL, Klimstra DS, Maitra A, Hruban RH and Argani P. Immunohistochemical and genetic analysis of non-small cell and small cell gallbladder carcinoma and their precursor lesions. Mod Pathol. 2003; 16:299-308.
20. Yanagisawa N, Mikami T, Saegusa M and Okayasu I. More frequent beta-catenin exon 3 mutations in gallbladder adenomas than in carcinomas indicate different lineages. Cancer Res. 2001; 61:19-22.
21. Chan-On W, Nairismagi ML, Ong CK, Lim WK, Dima S, Pairojkul C, Lim KH, McPherson JR, Cutcutache I, Heng HL, Ooi L, Chung A, Chow P, Cheow PC, Lee SY, Choo SP, et al. Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers. Nat Genet. 2013; 45:1474-1478.
22. Hadd AG, Houghton J, Choudhary A, Sah S, Chen L, Marko AC, Sanford T, Buddavarapu K, Krosting J, Garmire L, Wylie D, Shinde R, Beaudenon S, Alexander EK, Mambo E, Adai AT, et al. Targeted, high-depth, next-generation sequencing of cancer genes in formalin-fixed, paraffin-embedded and fine-needle aspiration tumor specimens. J Mol Diagn. 2013; 15:234-247.
23. Luchini C, Capelli P, Fassan M, Simbolo M, Mafficini A, Pedica F, Ruzzenente A, Guglielmi A, Corbo V and Scarpa A. Next-Generation Histopathologic Diagnosis: A Lesson From a Hepatic Carcinosarcoma. J Clin Oncol. 2014: [Epub ahead of print].
24. Simbolo M, Gottardi M, Corbo V, Fassan M, Mafficini A, Malpeli G, Lawlor RT and Scarpa A. DNA qualification workflow for next generation sequencing of histopathological samples. PLoS One. 2013; 8:e62692.
25. Fassan M, Simbolo M, Bria E, Mafficini A, Pilotto S, Capelli P, Bencivenga M, Pecori S, Luchini C, Neves D, Turri G, Vicentini C, Montagna L, Tomezzoli A, Tortora G, Chilosi M, et al. High-throughput mutation profiling identifies novel molecular dysregulation in high-grade intraepithelial neoplasia and early gastric cancers. Gastric Cancer. 2013:[Epub ahead of print].
26. Farges O, Fuks D, Le Treut YP, Azoulay D, Laurent A, Bachellier P, Nuzzo G, Belghiti J, Pruvot FR and Regimbeau JM. AJCC 7th edition of TNM staging accurately discriminates outcomes of patients with resectable intrahepatic cholangiocarcinoma: By the AFC-IHCC-2009 study group. Cancer. 2011; 117:2170-2177.
27. Zamo A, Bertolaso A, van Raaij AW, Mancini F, Scardoni M, Montresor M, Menestrina F, van Krieken JH, Chilosi M, Groenen PJ and Scarpa A. Application of microfluidic technology to the BIOMED-2 protocol for detection of B-cell clonality. J Mol Diagn. 2012; 14:30-37.
28. Scarpa A, Sikora K, Fassan M, Rachiglio AM, Cappellesso R, Antonello D, Amato E, Mafficini A, Lambiase M, Esposito C, Bria E, Simonato F, Scardoni M, Turri G, Chilosi M, Tortora G, et al. Molecular typing of lung adenocarcinoma on cytological samples using a multigene next generation sequencing panel. PLoS One. 2013; 8:e80478.
29. Missiaglia E, Dalai I, Barbi S, Beghelli S, Falconi M, della Peruta M, Piemonti L, Capurso G, Di Florio A, delle Fave G, Pederzoli P, Croce CM and Scarpa A. Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway. J Clin Oncol. 2010; 28:245-255.
30. Endo M, Yamamoto H, Setsu N, Kohashi K, Takahashi Y, Ishii T, Iida K, Matsumoto Y, Hakozaki M, Aoki M, Iwasaki H, Dobashi Y, Nishiyama K, Iwamoto Y and Oda Y. Prognostic significance of AKT/mTOR and MAPK pathways and antitumor effect of mTOR inhibitor in NF1-related and sporadic malignant peripheral nerve sheath tumors. Clin Cancer Res 2013; 19:450-461.
31. Corbo V, Beghelli S, Bersani S, Antonello D, Talamini G, Brunelli M, Capelli P, Falconi M and Scarpa A. Pancreatic endocrine tumours: mutational and immunohistochemical survey of protein kinases reveals alterations in targetable kinases in cancer cell lines and rare primaries. Ann Oncol. 2012; 23:127-134.
32. Blechacz B, Komuta M, Roskams T and Gores GJ. Clinical diagnosis and staging of cholangiocarcinoma. Nat Rev Gastroenterol Hepatol. 2011; 8:512-522.
33. Bertuccio P, Bosetti C, Levi F, Decarli A, Negri E and La Vecchia C. A comparison of trends in mortality from primary liver cancer and intrahepatic cholangiocarcinoma in Europe. Ann Oncol. 2013; 24:1667-1674.
34. Kobayashi S, Boggon TJ, Dayaram T, Janne PA, Kocher O, Meyerson M, Johnson BE, Eck MJ, Tenen DG and Halmos B. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med. 2005; 352:786-792.
35. Kipp BR, Fritcher EG, Clayton AC, Gores GJ, Roberts LR, Zhang J, Levy MJ and Halling KC. Comparison of KRAS mutation analysis and FISH for detecting pancreatobiliary tract cancer in cytology specimens collected during endoscopic retrograde cholangiopancreatography. J Mol Diagn. 2010; 12:780-786.
36. O'Dell MR, Huang JL, Whitney-Miller CL, Deshpande V, Rothberg P, Grose V, Rossi RM, Zhu AX, Land H, Bardeesy N and Hezel AF. Kras(G12D) and p53 mutation cause primary intrahepatic cholangiocarcinoma. Cancer Res. 2012; 72:1557-1567.
37. Deshpande V, Nduaguba A, Zimmerman SM, Kehoe SM, Macconaill LE, Lauwers GY, Ferrone C, Bardeesy N, Zhu AX and Hezel AF. Mutational profiling reveals PIK3CA mutations in gallbladder carcinoma. BMC Cancer. 2011; 11:60.
38. Jang S, Chun SM, Hong SM, Sung CO, Park H, Kang HJ, Kim KP, Lee YJ and Yu E. High throughput molecular profiling reveals differential mutation patterns in intrahepatic cholangiocarcinomas arising in chronic advanced liver diseases. Mod Pathol. 2013: [Epub ahead of print].
39. Valle JW, Furuse J, Jitlal M, Beare S, Mizuno N, Wasan H, Bridgewater J and Okusaka T. Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials. Ann Oncol. 2014; 25:391-398.
40. Faris JE and Zhu AX. Targeted therapy for biliary tract cancers. J Hepatobiliary Pancreat Sci. 2012; 19:326-336.
41. Gwak GY, Yoon JH, Shin CM, Ahn YJ, Chung JK, Kim YA, Kim TY and Lee HS. Detection of response-predicting mutations in the kinase domain of the epidermal growth factor receptor gene in cholangiocarcinomas. J Cancer Res Clin Oncol. 2005; 131:649-652.
42. Andersen JB, Spee B, Blechacz BR, Avital I, Komuta M, Barbour A, Conner EA, Gillen MC, Roskams T, Roberts LR, Factor VM and Thorgeirsson SS. Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors. Gastroenterology. 2012; 142:1021-1031 e1015.
43. Leone F, Cavalloni G, Pignochino Y, Sarotto I, Ferraris R, Piacibello W, Venesio T, Capussotti L, Risio M and Aglietta M. Somatic mutations of epidermal growth factor receptor in bile duct and gallbladder carcinoma. Clin Cancer Res. 2006; 12:1680-1685.
44. Reinersman JM, Johnson ML, Riely GJ, Chitale DA, Nicastri AD, Soff GA, Schwartz AG, Sima CS, Ayalew G, Lau C, Zakowski MF, Rusch VW, Ladanyi M and Kris MG. Frequency of EGFR and KRAS mutations in lung adenocarcinomas in African Americans. J Thorac Oncol. 2011; 6:28-31.
45. Coulouarn C, Cavard C, Rubbia-Brandt L, Audebourg A, Dumont F, Jacques S, Just PA, Clement B, Gilgenkrantz H, Perret C and Terris B. Combined hepatocellular-cholangiocarcinomas exhibit progenitor features and activation of Wnt and TGFbeta signaling pathways. Carcinogenesis. 2012; 33:1791-1796.
46. Araki K, Shimura T, Suzuki H, Tsutsumi S, Wada W, Yajima T, Kobayahi T, Kubo N and Kuwano H. E/N-cadherin switch mediates cancer progression via TGF-beta-induced epithelial-to-mesenchymal transition in extrahepatic cholangiocarcinoma. Br J Cancer. 2011; 105:1885-1893.
47. Borger DR, Goyal L, Yau TC, Poon RT, Ancukiewicz M, Deshpande V, Christiani DC, Liebman HM, Yang H, Kim H, Ellwood-Yen K, Faris JE, Iafrate AJ, Kwak EL, Clark JW, Allen JN, et al. Circulating oncometabolite 2-hydroxyglutarate is a potential surrogate biomarker in patients with isocitrate dehydrogenase-mutant intrahepatic cholangiocarcinoma. Clin Cancer Res. 2014: [Epub ahead of print].